Pathologic Correlates of Nondemented Aging, Mild Cognitive Impairment, and Early-Stage Alzheimer's Disease

Cited by (511)

Items 101–200 of 511

1. Transgenic mouse models of Alzheimer's disease: phenotype and application.
   2003 · PubMed
2. Disease Tracking Markers for Alzheimer's Disease at the Prodromal (MCI) Stage
   Valeria Drago, Claudio Babiloni, David Bartrés‐Faz, Anna Caroli, Beatríz Bosch, Tilman Hensch, Mira Didic, Hans‐Wolfgang Klafki, Michela Pievani, Jorge Jovicich et al. · 2011 · Journal of Alzheimer s Disease
3. CSF biomarker levels in early and late onset Alzheimer's disease
   Femke H. Bouwman, Niki S.M. Schoonenboom, Nicolaas A. Verwey, Evert J. van Elk, Astrid Kok, Marinus A. Blankenstein, Philip Scheltens, Wiesje M. van der Flier · 2008 · Neurobiology of Aging
4. Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition
   Maj‐Linda B. Selenica, Leif Benner, Steven B. Housley, Barbara Manchec, Daniel C. Lee, Kevin R. Nash, Jay H. Kalin, Joel A. Bergman, Alan P. Kozikowski, Marcia N. Gordon et al. · 2014 · Alzheimer s Research & Therapy
5. A Systematic Review and Meta-Analysis of On-Road Simulator and Cognitive Driving Assessment in Alzheimer’s Disease and Mild Cognitive Impairment
   Megan A. Hird, Peter Egeto, Corinne Eleanor Fischer, Gary Naglie, Tom A. Schweizer · 2016 · Journal of Alzheimer s Disease
6. Comparison of Pittsburgh compound B and florbetapir in cross‐sectional and longitudinal studies
   Yi Su, Shaney E. Flores, Guoqiao Wang, Russ C. Hornbeck, Benjamin A. Speidel, Nelly Joseph‐Mathurin, Andrei G. Vlassenko, Brian Andrew Gordon, Robert A. Koeppe, William Edward Klunk et al. · 2019 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
7. Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease
   Vana, Laurel, Kanaan, Nicholas M., Ugwu, Isabella C., Wuu, Joanne, Mufson, Elliott J., Binder, Lester I. · 2011 · The American Journal of Pathology
8. The effectiveness of dyadic interventions for people with dementia and their caregivers
   Heehyul E. Moon, Kathryn Betts Adams · 2012 · Dementia
9. In Vivo Effects of ApoE and Clusterin on Amyloid-β Metabolism and Neuropathology
   David M. Holtzman · 2004 · Journal of Molecular Neuroscience
10. Neuropathologic Studies of the Baltimore Longitudinal Study of Aging (BLSA)
    O'Brien, Richard J., Resnick, Susan M., Zonderman, Alan B., Ferrucci, Luigi, Crain, Barbara J., Pletnikova, Olga, Rudow, Gay, Iacono, Diego, Riudavets, Miguel A., Driscoll, Ira et al. · 2009 · Journal of Alzheimer's Disease
11. Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: Correlation with Alzheimer's neuropathology
    M. Ikonomovic, E. Mufson, J. Wuu, E. Cochran, D. Bennett, S. DeKosky · 2003 · Journal of Alzheimer's Disease
12. Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult
    William I. Rosenblum · 2013 · Neurobiology of Aging
13. Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies
    Su, Yi, Flores, Shaney, Hornbeck, Russ C., Speidel, Benjamin, Vlassenko, Andrei G., Gordon, Brian A., Koeppe, Robert A., Klunk, William E., Xiong, Chengjie, Morris, John C. et al. · 2018 · NeuroImage: Clinical
14. Core biological marker candidates of Alzheimer?s disease ? perspectives for diagnosis, prediction of outcome and reflection of biological activity
    Harald Juergen Hampel, Alex J. Mitchell, Kaj Blennow, Richard Frank, Sylvia Brettschneider, Lindsey Jean Ross Weller, H.-J. M�ller · 2004 · Journal of Neural Transmission
15. Asymptomatic Alzheimers Disease: A Prodrome or a State of Resilience?
    Driscoll, I., Troncoso, J. · 2011 · Current Alzheimer Research
16. [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease
    Ryuichi Harada, Nobuyuki Okamura, Shozo Furumoto, Katsutoshi Furukawa, Aiko Ishiki, Naoki Tomita, Kotaro Hiraoka, Shoichi Watanuki, Miho Shidahara, Masayasu Miyake et al. · 2015 · European Journal of Nuclear Medicine and Molecular Imaging
17. Sleep Deprivation Affects Tau Phosphorylation in Human Cerebrospinal Fluid
    Nicolas R. Barthélemy, Haiyan Liu, William Lu, Paul T. Kotzbauer, Randall John Bateman, Brendan P. Lucey · 2020 · Annals of Neurology
18. Transgenic mice overexpressing reticulon 3 develop neuritic abnormalities
    Xiangyou Hu, Qi Shi, Xiangdong Zhou, Wanxia He, Hong Liang Yi, Xinghua Yin, Marla Gearing, Allan I. Levey, Riqiang Yan · 2007 · The EMBO Journal
19. The PREVENT study: a prospective cohort study to identify mid-life biomarkers of late-onset Alzheimer's disease
    Craig William Ritchie, Karen A. Ritchie · 2012 · BMJ Open
20. Small-molecule PET Tracers for Imaging Proteinopathies
    Chester A. Mathis, Brian J. Lopresti, Miloš D. Ikonomović, William Edward Klunk · 2017 · Seminars in Nuclear Medicine
21. Dementia Games: A Literature Review of Dementia-Related Serious Games
    Simon McCallum, Costas Boletsis · 2013 · Lecture notes in computer science
22. Longitudinal changes of CSF biomarkers in memory clinic patients
    Femke H. Bouwman, Wiesje M. van der Flier, Niki S.M. Schoonenboom, Evert J. van Elk, Astrid Kok, Frank Rijmen, Marinus A. Blankenstein, Philip Scheltens · 2007 · Neurology
23. Comparative Proteomic Analysis of Intra- and Interindividual Variation in Human Cerebrospinal Fluid
    Yan Hu, James P. Malone, Anne M. Fagan, R. Reid Townsend, David M. Holtzman · 2005 · Molecular & Cellular Proteomics
24. A Double-Blind, Placebo-Controlled, Ascending-Dose, Randomized Study to Evaluate the Safety, Tolerability and Effects on Cognition of AL-108 after 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive Impairment
    Morimoto, Bruce H., Schmechel, Don, Hirman, Joe, Blackwell, Andrew, Keith, Julian, Gold, Michael, on behalf of the AL-108-211 Study Investigators · 2013 · Dementia and Geriatric Cognitive Disorders
25. Complement activation in very early Alzheimer disease
    Zanjani, H, Finch, C E, Kemper, C, Atkinson, J, McKeel, D, Morris, J C, Price, J L · 2005 · Alzheimer Disease & Associated Disorders
26. Aβ-amyloid and Tau Imaging in Dementia
    Villemagne, Victor L., Doré, Vincent, Bourgeat, Pierrick, Burnham, Samantha C., Laws, Simon, Salvado, Olivier, Masters, Colin L., Rowe, Christopher C. · 2017 · Seminars in Nuclear Medicine
27. Biomarker discovery in neurodegenerative diseases: A proteomic approach
    Min Yan Shi, William Michael Caudle, Jing Zhang · 2008 · Neurobiology of Disease
28. Cognitive deficits in preclinical Alzheimer's disease
    Brent J. Small, Jennifer L. Mobly, Erika J. Laukka, Sari Jones, Lars Bäckman · 2003 · Acta Neurologica Scandinavica
29. The Who, When, Why, and How of PET Amyloid Imaging in Management of Alzheimer’s Disease—Review of Literature and Interesting Images
    Suppiah, Subapriya, Didier, Mellanie-Anne, Vinjamuri, Sobhan · 2019 · Diagnostics
30. The Effects of Prolonged Stress and APOE Genotype on Memory and Cortisol in Older Adults
    Guerry M. Peavy, Kelly L. Lange, David P. Salmon, Thomas L. Patterson, Sherry Goldman, Anthony C. Gamst, Paul J. Mills, Srikrishna Khandrika, Douglas R Galasko · 2007 · Biological Psychiatry
31. Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia
    for the members of the Alzheimer’s Disease Cooperative Study Group*, Elisabeth C.W. van Straaten, D. Harvey, Philip Scheltens, Frederik Barkhof, Ronald Carl Petersen, Leon J. Thal, Clifford R. Jack, Charles S DeCarli · 2008 · Journal of Neurology
32. CSF Aβ42, Tau and phosphorylated Tau, APOE ɛ4 allele and MCI type in progressive MCI
    Sanna‐Kaisa Herukka, Seppo Helisalmi, Merja Hallikainen, Susanna Tervo, Hilkka S. Soininen, Tuula Pirttilä · 2006 · Neurobiology of Aging
33. Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer’s disease
    Patrizia Giannoni, Florence Gaven, Dimitri De Bundel, Kévin Baranger, E Marchetti, François S. Roman, Emmanuel Valjent, Philippe Marin, Joël Bockaert, Santiago Rivera et al. · 2013 · Frontiers in Aging Neuroscience
34. Beyond mild cognitive impairment: vascular cognitive impairment, no dementia (VCIND)
    Blossom C. M. Stephan, Fiona E. Matthews, Kay‐Tee Khaw, Carole Dufouil, Carol Brayne · 2009 · Alzheimer s Research & Therapy
35. Adapting Mini‐Mental State Examination for dementia screening among illiterate or minimally educated elderly Chinese
    Gelin Xu, John Stirling Meyer, Yuan‐Gui Huang, Fang Du, Munir H. Chowdhury, Minh Quach · 2003 · International Journal of Geriatric Psychiatry
36. Verbal Fluency and Early Memory Decline: Results from the Wisconsin Registry for Alzheimer's Prevention
    Kimberly Diggle Mueller, Rebecca L. Koscik, Asenath A. LaRue, Lindsay R. Clark, Bruce P. Hermann, Sterling C. Johnson, Mark A. Sager · 2015 · Archives of Clinical Neuropsychology
37. Parkinsonian signs in subjects with mild cognitive impairment
    Patricia A. Boyle, Robert S. Wilson, Neelum T. Aggarwal, Zoe Arvanitakis, J. Kelly, Julia L. Bienias, David Alan Bennett · 2005 · Neurology
38. Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons
    Riudavets, Miguel Angel, Iacono, Diego, Resnick, Susan M., O’Brien, Richard, Zonderman, Alan B., Martin, Lee J., Rudow, Gay, Pletnikova, Olga, Troncoso, Juan C. · 2007 · Neurobiology of Aging
39. Increased fragmentation of sleep–wake cycles in the 5XFAD mouse model of Alzheimer’s disease
    M. Sethi, Shreyas Joshi, Robin L. Webb, Tina L. Beckett, Kevin D. Donohue, M.P. Murphy, Bruce F. O’Hara, Marilyn J. Duncan · 2015 · Neuroscience
40. Plasma levels of amyloid β-protein 42 are increased in women with mild cognitive impairment
    Andrea Assini, S. Cammarata, Antonella Vitali, Maria Eduarda Waldemarin Colucci, Luca Giliberto, Roberta Borghi, M. L. Inglese, S. Volpe, Sandra Ratto, Francesca Dagna-Bricarelli et al. · 2004 · Neurology
41. Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models
    Joshua Aaron Sonnen, John C.S. Breitner, Mark A. Lovell, William R. Markesbery, Joseph F. Quinn, Thomas Jude Montine · 2008 · Free Radical Biology and Medicine
42. Alterations of Zinc Transporter Proteins ZnT‐1, ZnT‐4 and ZnT‐6 in Preclinical Alzheimer's Disease Brain
    Ganna Lyubartseva A, Jennifer L. Smith, William R. Markesbery, Mark A. Lovell · 2009 · Brain Pathology
43. Conceptual Evolution in Alzheimer's Disease: Implications for Understanding the Clinical Phenotype of Progressive Neurodegenerative Disease
    Gregory A. Jicha, Sarah A. Carr · 2010 · Journal of Alzheimer s Disease
44. Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease
    Schindler, Suzanne E., Li, Yan, Todd, Kaitlin W., Herries, Elizabeth M., Henson, Rachel L., Gray, Julia D., Wang, Guoqiao, Graham, Danielle L., Shaw, Leslie M., Trojanowski, John Q. et al. · 2019 · Alzheimer's & Dementia
45. Characteristics of Tau and Its Ligands in PET Imaging
    Ryuichi Harada, Nobuyuki Okamura, Shozo Furumoto, Tetsuro Tago, Kazuhiko Yanai, Hiroyuki Arai, Yukitsuka Kudo · 2016 · Biomolecules
46. Synergistic interaction between amyloid and tau predicts the progression to dementia
    Pascoal, Tharick A., Mathotaarachchi, Sulantha, Shin, Monica, Benedet, Andrea L., Mohades, Sara, Wang, Seqian, Beaudry, Tom, Kang, Min Su, Soucy, Jean‐Paul, Labbe, Aurelie et al. · 2017 · Alzheimer's & Dementia
47. Oxidative stress and hippocampal synaptic protein levels in elderly cognitively intact individuals with Alzheimer’s disease pathology
    Scheff, Stephen W., Ansari, Mubeen A., Mufson, Elliott J. · 2016 · Neurobiology of Aging
48. Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta
    Ann D. Cohen, Gil Dan Rabinovici, Chester A. Mathis, William J. Jagust, William Edward Klunk, Miloš D. Ikonomović · 2012 · Advances in pharmacology
49. The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias
    Victor L. Villemagne, Michelle T. Fodero‐Tavoletti, Kerryn Elizabeth Pike, Roberto Cappai, Colin Louis Masters, Christopher Cleon Rowe · 2008 · Molecular Neurobiology
50. Passive anti-amyloid β immunotherapy in Alzheimer's disease—opportunities and challenges
    Michael Thomas Heneka, David Morgan, Frank Jessen · 2024 · The Lancet
51. Visuospatial Perception: An Emerging Biomarker for Alzheimer's Disease
    Pravat Kumar Mandal, Jitesh Joshi, Sumiti Saharan · 2012 · Journal of Alzheimer s Disease
52. Brain aerobic glycolysis functions and Alzheimer’s disease
    Andrei G. Vlassenko, Marcus E. Raichle · 2014 · Clinical and Translational Imaging
53. Oxidative Damage, Protein Synthesis, and Protein Degradation in Alzheimers Disease
    Qunxing Ding, Edgardo R. Dimayuga, Jeffrey N. Keller · 2007 · Current Alzheimer Research
54. Fast Axonal Transport Misregulation and Alzheimer's Disease
    Gerardo A. Morfini, Gustavo F. Pigino, Uwe Beffert, Jorge A. Busciglio, Scott T. Brady · 2002 · NeuroMolecular Medicine
55. Mild cognitive impairment: Conceptual issues and structural and functional brain correlates
    Andrew J. Saykin, Heather A. Wishart · 2003 · Seminars in Clinical Neuropsychiatry
56. Postoperative cognitive dysfunction, Alzheimer's disease, and anesthesia
    Sona Shah Arora, Jennifer L. Gooch, Paul S. García · 2013 · International Journal of Neuroscience
57. Advances in the development of biomarkers for Alzheimer’s disease: from CSF total tau and Aβ1–42 proteins to phosphorylated tau protein
    Harald Juergen Hampel, Alexander Goernitz, Katharina Büerger · 2003 · Brain Research Bulletin
58. Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease
    Toledo, Jon B., Bjerke, Maria, Da, Xiao, Landau, Susan M., Foster, Norman L, Jagust, William, Jack, Clifford, Weiner, Michael, Davatzikos, Christos, Shaw, Leslie M. et al. · 2015 · JAMA Neurology
59. Effects of hardware heterogeneity on the performance of SVM Alzheimer's disease classifier
    Ahmed Abdulkadir, Bénédicte Mortamet, Prashanthi Vemuri, Clifford R. Jack, Gunnar Krüger, Stefan Klöppel · 2011 · NeuroImage
60. Impaired verb fluency: A sign of mild cognitive impairment
    Per Östberg, Sven‐Erik Fernaeus, Åke Hellström, Nenad Bogdanović, Lars‐Olof Wahlund · 2005 · Brain and Language
61. Vascular factors in dementia: an overview
    Charles S DeCarli · 2004 · Journal of the Neurological Sciences
62. Hippocampal mean diffusivity and memory in healthy elderly individuals
    Giovanni Augusto Carlesimo, Andrea Cherubini, Carlo Caltagirone, Gianfranco Spalletta · 2010 · Neurology
63. Hippocampal Volumes, Proton Magnetic Resonance Spectroscopy Metabolites, and Cerebrovascular Disease in Mild Cognitive Impairment Subtypes
    Kejal Kantarci, Ronald Carl Petersen, Scott A. Przybelski, Stephen D. Weigand, Maria M. Shiung, Jennifer Louise Whitwell, Selam Negash, Robert J. Ivnik, Bradley F. Boeve, David S. Knopman et al. · 2008 · Archives of Neurology
64. Cerebrospinal Fluid Biomarkers of Alzheimer's Disease
    Anne M. Fagan, David M. Holtzman · 2010 · Biomarkers in Medicine
65. [11C]PIB-amyloid binding and levels of Aβ40 and Aβ42 in postmortem brain tissue from Alzheimer patients
    Marie M. Svedberg, Håkan Hall, Ewa Hellström‐Lindahl, Sergio Estrada, Zhi-Zhong Guan, Agneta K. Nordberg, Bengt Långström · 2008 · Neurochemistry International
66. The Predicted Key Molecules, Functions, and Pathways That Bridge Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)
    Ye Tao, Yu Han, Lujiao Yu, Qi Wang, Sean Xiao Leng, Haiyan Zhang · 2020 · Frontiers in Neurology
67. A Review on Tramiprosate (Homotaurine) in Alzheimer's Disease and Other Neurocognitive Disorders
    Sagrario Manzano, Luis Agüera, Miquel Aguilar, Javier Olazarán · 2020 · Frontiers in Neurology
68. Auditory brain-stem, middle- and long-latency evoked potentials in mild cognitive impairment
    Rie Irimajiri, Edward J. Golob, Arnold Starr · 2005 · Clinical Neurophysiology
69. Longitudinal Assessment of Tau Pathology in Patients with Alzheimer’s Disease Using [18F]THK-5117 Positron Emission Tomography
    Aiko Ishiki, Nobuyuki Okamura, Katsutoshi Furukawa, Shozo Furumoto, Ryuichi Harada, Naoki Tomita, Kotaro Hiraoka, Shoichi Watanuki, Yoichi Ishikawa, Tetsuro Tago et al. · 2015 · PLoS ONE
70. Role of HIV in Amyloid Metabolism
    Mario Ortega, Beau M. Ances · 2014 · Journal of Neuroimmune Pharmacology
71. Fibroblast phenotype in male carriers of FMR1 premutation alleles
    Dolores Garcia-Arocena, Jane E. Yang, Judith Rixt Brouwer, Flora Tassone, Christine Iwahashi, Elizabeth Berry‐Kravis, Christopher G. Goetz, Allison M. Sumis, Lili Zhou, Danh V. Nguyen et al. · 2009 · Human Molecular Genetics
72. Is sporadic Alzheimer′s disease a developmental disorder?
    Thomas Arendt, Jens Stieler, Uwe Ueberham · 2017 · Journal of Neurochemistry
73. Update on Biomarkers For Amyloid Pathology in Alzheimer’s Disease
    Nicholas James Ashton, Michael Schöll, Kerstin Heurling, Eleni Gkanatsiou, Erik Portelius, Kina Höglund, Gunnar Brinkmalm, Abdul Hye, Kaj Blennow, Henrik Zetterberg · 2018 · Biomarkers in Medicine
74. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration
    Kina Höglund, Silke Kern, Anna Zettergren, Anne Börjesson‐Hanson, Henrik Zetterberg, Ingmar Gr. Skoog, Kaj Blennow · 2017 · Translational Psychiatry
75. Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease
    Yan Hu, Ava Hosseini, John S. K. Kauwe, Julia Gross, Nigel J. Cairns, Alison Goate, Anne M. Fagan, R. Reid Townsend, David M. Holtzman · 2007 · PROTEOMICS - CLINICAL APPLICATIONS
76. Membrane trafficking in neuronal maintenance and degeneration
    Dong Wang, Chih‐Chiang Chan, Smita Cherry, P. Robin Hiesinger · 2012 · Cellular and Molecular Life Sciences
77. Preclinical AD Workgroup staging: Pathological correlates and potential challenges
    Jicha, Gregory A., Abner, Erin L., Schmitt, Frederick A., Kryscio, Richard J., Riley, Kathryn P., Cooper, Gregory E., Stiles, Nancy, Mendiondo, Marta S., Smith, Charles D., Van Eldik, Linda J. et al. · 2012 · Neurobiology of Aging
78. Cortical α7 Nicotinic Acetylcholine Receptor and β-Amyloid Levels in Early Alzheimer Disease
    Miloš D. Ikonomović, Lynn Wecker, Eric E. Abrahamson, Joanne Wuu, Scott Counts, Stephen D. Ginsberg, Elliott Jay Mufson, Steven Trent DeKosky · 2009 · Archives of Neurology
79. Dementia: Alzheimer pathology and vascular factors: From mutually exclusive to interaction
    Anouk G.W. van Norden, Ewoud J. van Dijk, Karlijn F. de Laat, Philip Scheltens, Marcel G.M. Olde-Rikkert, Frank‐Erik de Leeuw · 2011 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
80. A Clinical Approach to Mild Cognitive Impairment
    Paul B. Rosenberg, Deirdre M. Johnston, Constantine George Lyketsos · 2006 · American Journal of Psychiatry
81. Developmental origins of aging in brain and blood vessels: an overview
    Caleb E. Finch · 2004 · Neurobiology of Aging
82. Effect of ninjin'yoeito, a K ampo (traditional J apanese) medicine, on cognitive impairment and depression in patients with A lzheimer's disease: 2 years of observation
    Chiaki Kudoh, Ryutaro Arita, Mitsuru Honda, Taichi Kishi, Yasuhiro Komatsu, Hiroaki Asou, Masaru Mimura · 2015 · Psychogeriatrics
83. Cognitive impairment: classification by 1H magnetic resonance spectroscopy
    M. C. Martínez‐Bisbal, E. Arana, L. Martí‐Bonmatí, E. Mollá, B. Celda · 2004 · European Journal of Neurology
84. White Matter Hyperintensities as Early and Independent Predictors of Alzheimer's Disease Risk
    Marion Mortamais, Sylvaine Artéro, Karen A. Ritchie · 2014 · Journal of Alzheimer s Disease
85. The Framingham Brain Donation Program: Neuropathology Along the Cognitive Continuum
    Au, Rhoda, Seshadri, Sudha, Knox, Kristen, Beiser, Alexa, J. Himali, Jayandra, J. Cabral, Howard, Auerbach, Sanford, C. Green, Robert, A. Wolf, Philip, C. McKee, Ann · 2012 · Current Alzheimer Research
86. Cyclooxygenase-3 Gene Expression in Alzheimer Hippocampus and in Stressed Human Neural Cells
    Jian-Guo Cui, Hitoshi Kuroda, Naduviladath Vishvanath Chandrasekharan, Ricardo Palacios Peláez, Daniel L. Simmons, Nicolas Guillermo Bazan, Walter J. Lukiw · 2004 · Neurochemical Research
87. F2-Isoprostanes as Biomarkers of Late-onset Alzheimer’s Disease
    Thomas Jude Montine, Joseph F. Quinn, Jeffrey Alan Kaye, Jason D. Morrow · 2007 · Journal of Molecular Neuroscience
88. The application of optical coherence tomography angiography in Alzheimer's disease: A systematic review
    Olivia M. Rifai, Sarah McGrory, Cason B. Robbins, Dilraj Singh Grewal, Andy Liu, Sharon Fekrat, Tom MacGillivray · 2021 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
89. Amyloid imaging: Past, present and future perspectives
    Victor L. Villemagne · 2016 · Ageing Research Reviews
90. CSF Levels of Heart Fatty Acid Binding Protein are Altered During Early Phases of Alzheimer's Disease
    Davide Chiasserini, Lucilla Parnetti, Ulf Andréasson, Henrik Zetterberg, David Giannandrea, Paolo Calabresi, Kaj Blennow · 2011 · Journal of Alzheimer s Disease
91. Amyloid Imaging with PET in Early Alzheimer Disease Diagnosis
    Christopher Cleon Rowe, Victor L. Villemagne · 2013 · Medical Clinics of North America
92. Early Intervention Is Key to Successful Management of Alzheimer Disease
    Steven Trent DeKosky · 2003 · Alzheimer Disease & Associated Disorders
93. Sequence of Alzheimer disease biomarker changes in cognitively normal adults
    Jingqin Rosy Luo, Folasade Agboola, Elizabeth Grant, Colin Louis Masters, Marilyn Albert, Sterling C. Johnson, Eric McDade, Jonathan Vöglein, Anne M. Fagan, Tammie L.S. Benzinger et al. · 2020 · Neurology
94. Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ‐54861911, a potent oral BACE inhibitor
    Maarten Timmers, Bianca Van Broeck, Steven Ramael, John Slemmon, Katja De Waepenaert, Alberto Russu, Jennifer Bogert, Hans Stieltjes, Leslie M. J. Shaw, Sebastiaan Engelborghs et al. · 2016 · Alzheimer s & Dementia Translational Research & Clinical Interventions
95. Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images
    Nelleke Tolboom, Wiesje M. van der Flier, Jolanda Boverhoff, Maqsood M. Yaqub, Mike Peter Wattjes, Pieter G.H.M. Raijmakers, Frederik Barkhof, Philip Scheltens, Karl Herholz, Adriaan A. Lammertsma et al. · 2010 · Journal of Neurology Neurosurgery & Psychiatry
96. Braak staging, plaque pathology, and APOE status in elderly persons without cognitive impairment
    Elliott Jay Mufson, Michael H. Malek‐Ahmadi, Sylvia E. Perez, Kewei Chen · 2015 · Neurobiology of Aging
97. Role of Family History for Alzheimer Biomarker Abnormalities in the Adult Children Study
    Xiong, Chengjie · 2011 · Archives of Neurology
98. Evidence for the Involvement of Apoptosis-Inducing Factor–Mediated Caspase-Independent Neuronal Death in Alzheimer Disease
    Wenfeng Yu, Naguib Mechawar, Slavica M Krantic, Rémi Quirion · 2010 · American Journal Of Pathology
99. Brief Screening Tests for the Diagnosis of Dementia: Comparison With the Mini-Mental State Exam
    Sandy Kilada, Alyssa A Gamaldo, Elizabeth Grant, Abhay Moghekar, John C. Morris, Richard O’Brien · 2005 · Alzheimer Disease & Associated Disorders
100. Maladaptive Behaviors Related to Dementia Status in Adults With Down Syndrome
     Tiina K. Urv, Warren B. Zigman, Wayne P. Silverman · 2008 · American Journal on Mental Retardation